化学免疫治疗在ALK重组的晚期肺状细胞癌中的高效性:一个病例报告

Yongliang Niu1, Bowen Ding2, Jingfeng Shi1

  • 1Department of Respiratory and Critical Care Medicine, No.2 People's Hospital of Fuyang City, Fuyang Infectious Disease Clinical College of Anhui Medical University, Fuyang, 236000, People's Republic of China.

PubMed
概括

无细胞淋巴瘤激酶 (ALK) 的重组在肺状细胞癌中很罕见. 化疗免疫疗法在耐药病例中显示出显著的长期益处,这表明它有可能对先进的ALK重组的LSCC产生影响.